One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus

E.J.P. van Asseldonk, P.C.M. van Poppel, D.B. Ballak, Rinke Stienstra*, M.G. Netea, C.J. Tack

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

32 Citations (Scopus)

Abstract

Inflammation associated with obesity is involved in the development of insulin resistance. We hypothesized that anti-inflammatory treatment with the Interleukin-1 receptor antagonist anakinra would improve insulin sensitivity.In an open label proof-of-concept study, we included overweight patients diagnosed with type 1 diabetes with an HbA1c level over 7.5%. Selecting insulin resistant patients with longstanding type 1 diabetes allowed us to study the effects of anakinra on insulin sensitivity. Patients were treated with 100. mg anakinra daily for one week. Insulin sensitivity, insulin need and blood glucose profiles were measured before, after one week and after four weeks of follow-up.Fourteen patients completed the study. One week of anakinra treatment led to an improvement of insulin sensitivity, an effect that was sustained for four weeks. Similarly, glucose profiles, HbA1c levels and insulin needs improved.In conclusion, one week of treatment with anakinra improves insulin sensitivity in patients with type 1 diabetes.

Original languageEnglish
Pages (from-to)155-162
JournalClinical Immunology
Volume160
Issue number2
DOIs
Publication statusPublished - 2015

Keywords

  • Adipose tissue
  • Anakinra
  • Inflammation
  • Insulin sensitivity
  • Interleukin 1
  • Type 1 diabetes

Fingerprint Dive into the research topics of 'One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus'. Together they form a unique fingerprint.

Cite this